Nephro Care India Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Nephro Care India Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹90
Per ShareLot Size
1600 Shares
Minimum Investment
₹1,44,000
Issue Size
₹41.26 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Nephro Care India Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
84.02%
Promoter Holding (Post-Issue)
60.66%
Issue Type
Book Building - SME
ISIN
INE0SUN01013
About the Company
Nephro Care was founded in the year 2014 by Dr. Pratim Sengupta in Kolkata with an object of providing comprehensive medical services for renal patients. As on date, Nephro Care is a one stop treatment centre based in Kolkata that offers a wide range of clinical and lifestyle solutions and services and renal insufficiency treatment to patients. The treatment framework covers the entire range of lifestyle, physiological and spiritual aspects of wellness. The operations of Nephro Care are supported by a pool of expert Doctors, experienced and well-trained paramedical professionals and a skilled management team. The entire team at Nephro Care is supported by sufficient clinical and investigative infrastructure.
Industry Overview
CKD is a severe public health issue in India. As per government estimates, nearly 2,20,000 patients develop end-stage renal disease (ESRD) annually in India, leading to an additional annual dialysis demand of 34 million treatment sessions. Unfortunately, in India, renal insufficiency treatment focuses more on curative nephrology rather than preventive and holistic solutions. Kidney disease is a significant public health concern in India, with high morbidity and mortality rates. The Million Death Study estimated a 50% increase in deaths due to chronic kidney disease (CKD) between 2001-2003 and 2010-2013. Several surveys have shown a high population prevalence of CKD. As many as one out of every five adults in high-prevalence areas has CKD. Similarly, acute kidney injury is common and carries a high mortality, especially because treatment is frequently delayed. However, the National Programme for Prevention & Control of Cancer, Diabetes, Cardio-vascular diseases and Stroke (NPCDCS), the flagship NCD prevention programme in India, does not cover kidney care.
Company History
Our Company was originally incorporated on July 08, 2014 as a Private Limited Company as "Nephro Care India Private Limited" under the provisions of the Companies Act, 2013 with the Registrar of Companies, West Bengal. Subsequently, our Company was converted into a public limited company pursuant to a resolution passed by our Shareholders at an extraordinary general meeting held on December 26, 2023 and consequently the name of our Company was changed to `Nephro Care India Limited' and a fresh certificate of incorporation dated March 5, 2024, was issued by the Registrar of Companies, Central Processing Centre. The corporate identification number of our Company is U85100WB2014PLC202429.
Growth Strategy
- Continue to invest in extension of our Hub-and-Spoke network.
- Continue to attract, engage and train prominent, skilled doctors and other healthcare professionals.
- Enhance clinical capabilities and improve operating efficiencies.
- Extend clinical services outside the clinic and across the lifetime of the patient.
- Leverage technology to improve patient experience and grow our digital health services.
- Build on our thought leadership through increased focus on academics and research.
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY23 to FY25.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Public issue of 45,84,000 equity shares of face value of Rs. 10 each ("Equity Shares") of Nepho Care India Limited (the "Company" or the "Issuer") for cash at a price of Rs. 90 per equity (the "Issue Price") aggregating to Rs. 41.26 crores ("The Issue") comprising of a fresh issue of 45,84,000 equity shares aggregating to Rs. 41.26 crores (the "Fresh Issue") of which 2,25,600 equity shares aggregating to Rs. 2.03 crores will be reserved for subscription by eligible employees of the company (the "Employees Reservation Portion") and 2,30,400 equity shares aggregating to Rs. 2.07 crores will be reserved for subscription by market maker to the issue (the "Market Maker Reservation Portion"). The issue less the employees reservation portion and the market maker reservation portion i.e. net issue of 41,28,000 equity shares aggregating to Rs. 37.15 crores (the "Net Issue"). The issue and the net issue will constitute 27.80% and 25.04 % respectively of the post issue paid up equity share capital of the company. The Offer Price is Rs. 90 per equity share of face value of Rs. 10/- each. The issue price is 9.00 times of the face value of the equity shares. Bid can be made for minimum of 1600 equity shares and the multiples of 1600 equity shares thereafter.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- We bridge the gap between day care and tertiary care services by addressing unmet needs through a blend of modern medical science and time tested yogic wisdom for overall wellbeing of the patients.
- Our technology backbone is robust and supports consistent improvements in the quality and efficiency of our service delivery.
- Track record of operating and financial performance and growth.
- Professional management and experienced leadership.
- Investment in infrastructure, processes and clinical services delivery framework, affordability resulting in a strong value proposition for stakeholders.
- Its Promoter, Dr. Pratim Sengupta, plays a key role in the company functioning and its heavily relies on his knowledge and experience in operating its business and therefore, it is critical for the company's business that its Promoter remain associated with the company.
- Its expansion into new business vertical, i.e. setting up a hospital, may expose the company to new challenges and more risks.
- The company's revenues are significantly dependent on its flagship Salt Lake clinic. Further, all its clinics are located in the Kolkata. Any impact on the revenues of its flagship Salt Lake clinic or any change in the economic or political circumstances of West Bengal or particularly in or around Kolkata, could materially affect its business, financial condition and results of operations.
- The company is highly dependent on its healthcare professionals including doctors and nurses, and any future inability to attract/ retain such professionals will adversely affect its business, financial condition and results of operations.
- Its industry is highly regulated and requires it to obtain, renew and maintain statutory and regulatory permits, accreditations, licenses and comply with applicable safety, health, environmental, labour and other governmental regulations. Any regulatory changes or violations of such rules and regulations may adversely affect its business, financial condition and results of operations.